ADC Therapeutics SA — Form 6-K Summary
Reporting period: Form 6-K for August 2021, filed August 26, 2021. The filing reports a material financing and royalty transaction entered into on August 25, 2021. It does not provide quarterly or annual operating results.
Transaction and Key Financial Terms
- ADC Therapeutics agreed to sell certain royalties on ZYNLONTA (loncastuximab tesirine) and camidanlumab tesirine (Cami) to entities managed by HealthCare Royalty Management, LLC.
- ADC is entitled to receive $225 million at closing, $75 million upon the first commercial sale of ZYNLONTA in the United Kingdom or a European Union country, and $25 million upon achievement of a specified low nine-digit worldwide 2022 ZYNLONTA net-sales milestone, excluding certain Asian markets.
- In exchange, ADC will pay HealthCare Royalty a 7% royalty on specified ZYNLONTA sales and related licensing receipts, and a 7% royalty or specified share of licensing economics on Cami. Certain rates may increase after September 30, 2026 or September 30, 2027 if sales and licensing thresholds are not met.
- Aggregate royalty obligations are capped at 2.50 times the amount paid by HealthCare Royalty, or 2.25 times if specified royalty payments are received by March 31, 2029.
- Closing was expected within 15 business days after August 25, 2021. The filing does not confirm that closing had occurred as of the filing date.
Material Changes, Debt and Liquidity
- ADC entered into a Limited Consent and Amendment with Deerfield relating to its existing Facility Agreement and convertible notes.
- The amendment permits certain payments under the royalty transaction and provides Deerfield with redemption and/or conversion rights, and requires funds to be set aside for existing obligations, in specified change-of-control and other circumstances.
- While Deerfield indebtedness remains outstanding, ADC generally may not incur new debt other than unsecured debt of up to $125 million. After repayment of the Facility Agreement debt, new indebtedness generally may not exceed 20% of ADC’s market capitalization at the time incurred.
- The filing does not provide current cash, cash-flow, debt-balance, liquidity, revenue, profit, or margin figures.
Outlook, Covenants and Risks
- ADC agreed to use commercially reasonable efforts to develop and commercialize ZYNLONTA and Cami in specified major markets and to follow a specified product plan.
- ADC is restricted from selling, financing, or loaning additional royalties on specified ZYNLONTA territories or on Cami, subject to exceptions.
- In certain circumstances, HealthCare Royalty’s consent may be required for an exclusive U.S. ZYNLONTA license.
- Covenant breaches could require liquidated damages equal to 1.50 times HealthCare Royalty’s purchase amount, less prior payments, with termination of the agreement.
- Upon a change of control, ADC may owe the Royalty Cap, or 2.00 times HealthCare Royalty’s purchase amount if the event occurs before the 36-month anniversary of closing, less prior payments.
- After the 27-month anniversary of closing, ADC may buy out the remaining royalty obligations by paying the applicable Buyout Amount. HealthCare Royalty may instead elect to receive 50% of that amount and retain 50% of future royalty payments, subject to a reduced cap.
- The transaction creates a long-term obligation to share product sales and licensing economics and may limit future financing, licensing, and strategic flexibility.
Important Facts to Verify
- Whether the transaction closed and whether ADC received the initial $225 million payment.
- The final purchase price, royalty cap, milestone definitions, and omitted confidential provisions in Exhibit 99.1.
- ADC’s outstanding Deerfield debt, convertible-note terms, and any resulting changes to repayment, conversion, or default provisions.
- The precise territories, products, licensing receipts, and sales included in the royalty calculation.
- The effects of the transaction on ADC’s liquidity, commercialization plans, and future financing capacity.